Document is current
Any future updates will be listed below
-
Authors
Cralley, Alexis L. https://orcid.org/0000-0003-4021-7565
Moore, Ernest E.
Coleman, Julia R.
Vigneshwar, Navin
Bartley, Matt
Kissau, Daniel
Eitel, Andrew
Hom, Patrick
Mitra, Sanchayita
Ghasabyan, Arsen
Fragoso, Miguel
Guo, Zihan
Deguchi, Hiroshi
Griffin, John H.
Cohen, Mitchell J.
Silliman, Christopher C.
Banerjee, Anirban
Hansen, Kirk
Sauaia, Angela
-
Funding
Funding for this research was provided by:
TACTIC (UM1-HL120877)
National Institute of General Medical Sciences (T32 GM008315)
- License Information
-
More Information
Article History
Received: 11 July 2022
Accepted: 14 October 2022
First Online: 1 November 2022
Declarations
:
: E.E.M. has patents pending related to coagulation and fibrinolysis diagnostics and therapeutic fibrinolytics and is a cofounder with stock options in ThromboTherepeutics. E.E.M. has received grant support from Haemonetics, Inc., Stago, Hemosonics, Instrumentation Laboratories, Inc, and Diapharma outside the submitted work.
: This animal study was conducted in compliance with the Animal Welfare Act, implementing Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory Animals, National Research Council. Results are reported in accordance with the ARRIVE guidelines [1]. The University of Colorado Institutional Animal Care and Use Committee approved this animal study under protocol #0323, and the research was conducted in a fully accredited Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) facility.
